Table 1.

Comparisons of the ROC-AUCs for CA125 and HE4 across the groups enrolled in this study

		CA125 ROC-AUC (95% CI)	HE4 ROC-AUC (95% CI)	p-value
Post-menopause	EOC vs HC	0.9940 (0.9866–1.0000)	0.9576 (0.9279–0.9873)	0.0147
	EOC vs Cysts	0.9602 (0.9353–0.9852)	0.9400 (0.9039–0.97599)	0.2439
	Cysts vs HC	0.6671 (0.5898–0.7444)	0.5856 (0.5055–0.6656)	0.1420
Pre-menopause	EOC vs HC	0.9773 (0.9457–1.0000)	0.9177 (0.8279–1.0000)	0.1233
	EOC vs Cysts	0.9549 (0.9053–1.0000)	0.9016 (0.8068–0.9965)	0.1867
	EOC vs End	0.8473 (0.7397–0.9549)	0.8925 (0.7907–0.9944)	0.3211
	Cysts vs HC	0.5960 (0.4644–0.7275)	0.5744 (0.4390–0.7097)	0.8280
	End vs HC	0.8982 (0.8183–0.9781)	0.6369 (0.5055–0.7682)	0.0011
	End vs Cysts	0.8361 (0.7307–0.9416)	0.5471 (0.4075–0.6867)	0.0019

ROC-AUC, area under the receiver operating characteristic curve; HE4, human epididymis protein 4; CI, confidence interval; HC, healthy controls; Cysts, patients with ovarian benign cysts; End, patients with endometriosis; EOC, patients with epithelial ovarian cancer